Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Cash & Equivalents (2023 - 2026)

BioAge Labs' Cash & Equivalents history spans 3 years, with the latest figure at $188.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 46.69% to $188.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $188.9 million, a 46.69% decrease, with the full-year FY2025 number at $188.9 million, down 46.69% from a year prior.
  • Cash & Equivalents hit $188.9 million in Q4 2025 for BioAge Labs, down from $215.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BIOA hit a ceiling of $354.3 million in Q4 2024 and a floor of $21.6 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $220.8 million across 3 years, with a median of $217.8 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 1537.17% in 2024 and later crashed 46.69% in 2025.
  • Tracing BIOA's Cash & Equivalents over 3 years: stood at $21.6 million in 2023, then skyrocketed by 1537.17% to $354.3 million in 2024, then crashed by 46.69% to $188.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for BIOA at $188.9 million in Q4 2025, $215.6 million in Q3 2025, and $220.0 million in Q2 2025.